CMT Summit + Retreat 2025
CMT Summit + Retreat 2025: Uniting Patients, Researchers, Regulators, and Industry Leaders to...
CATEGORIES: Applied Therapeutics | CMT Type - SORD Deficiency | CMT-Connect | CMT-Connect Webinars | Featured
SORD Webinar – Part 2 – Clinical Trial Update
Learn more on this topic
Related Blog Posts
Alesta Therapeutics Advances ALE2 to Target Rare Forms of CMT
Early preclinical research indicates that ALE2 could effectively slow or halt the progression of these debilitating symptoms, offering new hope for patients with these rare forms of CMT.
Welcome to the CMT Simplified Podcast by the HNF
CMT Simplified is here to make staying informed about Charcot-Marie-Tooth disease (CMT) easier...
HNF Awards the inaugural HNF Clinical Translation Fellowship
HNF Awards the inaugural HNF Clinical Translation Fellowship in the amount of $170,000 to Kayla...
Research Opportunity: CMT-SORD
Research Opportunity: CMT-SORD I am writing to you today because there is a research opportunity...
2024 CMT Roadshow Coming to a City Near You?
Do you want to make a difference in CMT research? HNF is looking for patients with a confirmed CMT diagnosis to participate in the CMT Biobank
Cannabis & CMT Webinar
Angie Roullier is the author of “Pot for the People: The plant, the people, and the shop policies of cannabis” – Cannabis Tutor/Patient Relations
Unstoppable Skyler Fisher: Triumphing Across Continents with CMT
In the fast-paced world of para triathlons, one name stands out among the rest: Skyler Fisher, a dynamic 19-year-old powerhouse representing Team USA.
Breaking News for SORD Deficiency Patients
The INSPIRE trial is a Phase 3 double-blind placebo-controlled registrational study evaluating the effect of once-daily (QD) oral govorestat (AT-007) in 56 patients aged 16-55 with SORD Deficiency in the US and Europe.
HNF Contributes CMTRN Data to C-Path’s RDCA-DAP
HNF Contributes CMTRN Data to C-Path’s RDCA-DAP, Strengthening Research Capabilities for Inherited...
0 Comments